CCM
APLS

CAAS Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

CAAS Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-250,000
Closed -$12.7M – 890
2022
Q1 		$12.7M Buy
+250,000
New +$11M 0.52% 55

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CAAS Capital Management's APLS Position: Q2 2022 in Review

CAAS Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2022, closing a stake of 250,000 shares — an estimated $12.7M sold.

CAAS Capital Management first reported a position in APLS in Q1 2022 and held it in 1 quarter. The position peaked at $12.7M in Q1 2022. 211 funds tracked by Wall St. Rank hold APLS as of Q2 2022.

  • CAAS Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • CAAS Capital Management sold 250,000 Apellis Pharmaceuticals shares in Q2 2022, an estimated $12.7M.
  • CAAS Capital Management first reported a position in Apellis Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • CAAS Capital Management's Apellis Pharmaceuticals position peaked at $12.7M in Q1 2022.
  • 211 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2022.

Based on CAAS Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.